LYMPHOMA COALITION

At ISPOR 2025, Marjorie Morrison, Director of Policy & Advocacy at Lymphoma Coalition, spoke with Dr. Tamás Ágh, Director of Strategy at Syreon Research Institute and Research Associate Professor at the University of Pécs.

Their conversation explored the challenges and opportunities in integrating patient-reported outcomes (PROs) into clinical trial design and decision-making processes.

Both Marjorie and Tamás serve on the ISPOR 2025 Program Committee, contributing their expertise to shape the conference’s focus on advancing health economics and outcomes research.

Watch their full discussion to learn how research and innovation are helping shape more patient-centred systems.

#ISPOR2025 #PatientCentredCare #lymsm ... See MoreSee Less

placeholder

Lorna Warwick, CEO of Lymphoma Coalition, discusses the abstract presented at ISPOR 2025:
“Patient Reported Adverse Psychosocial Outcomes and Identification of Predictive Factors in Those with Lymphoma or Chronic Lymphocytic Leukemia. An analysis of the Lymphoma Coalition's 2024 Global Patient Survey.”

The findings highlight the emotional and psychological impacts of a lymphoma or CLL diagnosis and the factors that may help identify those at greater risk. A deeper analysis revealed that younger patients are significantly more likely to experience multiple psychosocial challenges, more so than differences seen by gender, diagnosis, or disease stage.

These insights underscore the need for:
• Earlier psychosocial intervention
• Stronger patient-clinician communication
• Broader inclusion of psychosocial measures in clinical trials

Lymphoma Coalition advocates for the routine inclusion of patient-reported outcomes in research and care, to ensure treatment decisions reflect the full experience of those affected by lymphoma and CLL.

#ISPOR2025 #PatientCentredCare #lymsm ... See MoreSee Less

placeholder